Christian Rohlff MD

Dr Rohlff became Chief Executive of Oxford BioTherapeutics in 2004, after founding the company and acquiring key targeting technology, bioinformatics data and intellectual property. He brings more than 20 years of experience in the international biotechnology industry to OBT. Following his PhD in Pharmacology from Georgetown University, he held a number of positions at the US National Cancer Institute. Prior to joining OBT, he held a number of positions of increasing seniority with Oxford Glycosciences, and led the company’s partnerships in oncology with Pfizer, GSK, Bayer, Wyeth, Takeda, Oxford University and the FDA.